LB PHARMACEUTICALS INC (LBRX) competitors & alternatives
Health Care · NASDAQ
LB PHARMACEUTICALS INC (LBRX)'s top competitors and alternatives — its most similar public companies — include ASTRAZENECA PLC (AZN), Axsome Therapeutics, Inc. (AXSM), XENON PHARMACEUTICALS INC (XENE), ALKERMES (ALKS), DEFINIUM THERAPEUTICS INC (DFTX), OVID THERAPEUTICS INC (OVID), VANDA PHARMACEUTICALS INC (VNDA), NRX Pharmaceuticals, Inc. (NRXP), TONIX PHARMACEUTICALS HOLDING CORP (TNXP), ATAIBECKLEY INC (ATAI), ANAVEX LIFE SCIENCES CORP (AVXL) and TAYSHA GENE THERAPIES INC (TSHA). These are LB PHARMACEUTICALS INC's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top LBRX competitors & alternatives
-
ASTRAZENECA PLCAZN
Leading global biopharmaceutical company developing targeted oncology, cardiovascular, and rare disease treatments backed by a strong R&D pipeline.
$169.73 (as of 2026-07-22) · market cap $193.7B
-
Axsome Therapeutics, Inc.AXSMHealth Care
A fully integrated biopharmaceutical company developing innovative CNS treatments, with three FDA-approved commercial products and a deep pipeline of novel…
$239.62 (as of 2026-07-22) · market cap $12.3B
-
XENON PHARMACEUTICALS INCXENEHealth Care
A pre-commercial neuroscience biotech racing to bring azetukalner, a differentiated potassium channel opener, through Phase 3 trials for epilepsy and…
$66.18 (as of 2026-07-22) · market cap $6.7B
-
ALKERMESALKSHealth Care
Alkermes is a neuroscience-focused biopharmaceutical company commercializing branded therapies for schizophrenia, bipolar disorder, narcolepsy, and substance…
$52.58 (as of 2026-07-22) · market cap $8.8B
-
DEFINIUM THERAPEUTICS INCDFTXHealth Care
Definium is applying scientific rigor to psychedelics and empathogens to develop FDA-breakthrough-designated treatments for anxiety, depression, PTSD, and…
$43.67 (as of 2026-07-22) · market cap $5.8B
-
OVID THERAPEUTICS INCOVIDHealth Care
A biopharmaceutical company developing small molecule medicines targeting neuronal hyperexcitability to treat drug-resistant epilepsies, developmental…
$2.38 (as of 2026-07-22) · market cap $438M
-
VANDA PHARMACEUTICALS INCVNDAHealth Care
Niche biopharmaceutical company commercializing approved therapies for psychiatry, sleep disorders, and multiple sclerosis while pursuing pipeline expansion in…
$5.35 (as of 2026-07-22) · market cap $329M
-
NRX Pharmaceuticals, Inc.NRXPHealth Care
Clinical-stage biotech developing ketamine and NMDA receptor-modulating drugs for treatment-resistant depression, PTSD, and suicidal ideation with three…
$4.48 (as of 2026-07-22) · market cap $186M
-
TONIX PHARMACEUTICALS HOLDING CORPTNXPHealth Care
A fully-integrated biopharmaceutical company commercializing TONMYA (cyclobenzaprine sublingual tablets) for fibromyalgia while advancing a pipeline of CNS,…
$10.59 (as of 2026-07-22) · market cap $184M
-
ATAIBECKLEY INCATAIHealth Care
A clinical-stage biotechnology company dedicated to developing innovative mental health therapies through a diverse pipeline of neuropsychiatric treatments.
$7.18 (as of 2026-07-22) · market cap $2.7B
-
ANAVEX LIFE SCIENCES CORPAVXLHealth Care
Anavex is a clinical-stage biotech developing sigma-1 receptor agonists for neurodegenerative and rare CNS disorders, with lead program ANAVEX 2-73 in multiple…
$2.55 (as of 2026-07-22) · market cap $234M
-
TAYSHA GENE THERAPIES INCTSHAHealth Care
Taysha Gene Therapies is a clinical-stage biotech company pioneering AAV-based gene therapies to treat severe, rare monogenic diseases of the central nervous…
$5.66 (as of 2026-07-22) · market cap $1.8B
Not quite? Describe exactly what you want →
Peers are LB PHARMACEUTICALS INC's closest public companies by shared sub-industry, sector and business themes. See the full profile: LB PHARMACEUTICALS INC (LBRX).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.